74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Essa Pharma Inc
Closed
1.72 -0.58
Overview
Share price change
24h
Min
1.69
Max
1.72
Income | -2.2M -8.5M |
|---|---|
EPS | -0.272 |
Employees | 35 |
EBITDA | -3.6M -9.9M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +30.81 upside |
Market Cap | 77M |
|---|---|
Previous open | 2.3 |
Previous close | 1.72 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Essa Pharma Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Essa Pharma Inc Forecast
Price Target
By TipRanks
30.81% upside
12 Months Forecast
Average 2.25 USD 30.81%
High 2.25 USD
Low 2.25 USD
Based on 1 Wall Street analysts offering 12 month price targets forEssa Pharma Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Essa Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
